PE20030284A1 - Cepas de bifidobacterium - Google Patents

Cepas de bifidobacterium

Info

Publication number
PE20030284A1
PE20030284A1 PE2002000664A PE2002000664A PE20030284A1 PE 20030284 A1 PE20030284 A1 PE 20030284A1 PE 2002000664 A PE2002000664 A PE 2002000664A PE 2002000664 A PE2002000664 A PE 2002000664A PE 20030284 A1 PE20030284 A1 PE 20030284A1
Authority
PE
Peru
Prior art keywords
strain
gastrointestinal
bifidobacterium
inflammable
activity
Prior art date
Application number
PE2002000664A
Other languages
English (en)
Inventor
John Kevin Collins
Barry Kiely
Liam O'mahony
Fergus Shanhan
Gerald Chrispopher O'sullivan
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of PE20030284A1 publication Critical patent/PE20030284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter

Abstract

SE REFIERE A UNA CEPA DE BIFIDOBACTERIUM SELECCIONADA DE AH208, AH209, AH210, AH211, AH212, AH214 O UNA MUTANTE GENETICAMENTE MODIFICADA O VARIANTE DE ELLAS. LA CEPA PUEDE ESTA EN FORMA DE CELULAS VIABLES O NO VIABLES Y ES AISLADO A PARTIR DEL TRACTO GASTROINTESTINAL HUMANO RESECTADO Y LAVADO. LA CEPA ES CAPAZ DE ESTIMULAR LA PRODUCCION DE INTERLEUCINA -10. SE REFIERE TAMBIEN A UNA FORMULACION QUE COMPRENDE AL MENOS UNA DE LAS CEPAS Bifidobacterium PRESENTE EN UNA CANTIDAD MAYOR QUE 10 6 ufc POR GRAMO DE SISTEMA DE DISTRIBUCION Y UN MATERIAL PROBIOTICO UTILES EN EL TRATAMIENTO DE LA ACTIVIDAD INFLAMATORIA GASTROINTESTINAL INDESEABLE TALES COMO SINDROME DE COLON IRRITABLE
PE2002000664A 2001-07-26 2002-07-25 Cepas de bifidobacterium PE20030284A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IE20010711 2001-07-26
IE20010709 2001-07-26
IE20010714 2001-07-26
IE20010713 2001-07-26
IE20010710 2001-07-26
IE20010717 2001-07-26

Publications (1)

Publication Number Publication Date
PE20030284A1 true PE20030284A1 (es) 2003-05-01

Family

ID=27547373

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000664A PE20030284A1 (es) 2001-07-26 2002-07-25 Cepas de bifidobacterium

Country Status (12)

Country Link
US (2) US20030092163A1 (es)
EP (1) EP1409644A1 (es)
JP (1) JP2005508617A (es)
CN (1) CN1561387A (es)
AU (1) AU2002329006A1 (es)
BR (1) BR0211442A (es)
CA (1) CA2454803A1 (es)
IL (1) IL160048A0 (es)
IN (1) IN2004KO00093A (es)
MX (1) MXPA04000738A (es)
PE (1) PE20030284A1 (es)
WO (1) WO2003010297A1 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7182943B2 (en) * 2002-05-15 2007-02-27 UNIVERSITé LAVAL Method and system for modulation of microbial cell characteristics
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20060094056A1 (en) * 2003-09-15 2006-05-04 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
US8871266B2 (en) * 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
AU2004275438B2 (en) * 2003-10-01 2008-05-29 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
WO2005058335A1 (en) 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
WO2005072718A1 (ja) * 2004-01-28 2005-08-11 Kurume University 乳清発酵物を含有する医薬組成物
JP2005247780A (ja) * 2004-03-05 2005-09-15 Masakazu Maruyama ウイルス性肝炎治療剤
ES2262418B1 (es) * 2004-12-28 2007-11-01 Consejo Superior Investig. Cientificas Extractos proteicos con amplio espectro de actividad antibacteriana y cepas del genero bifidobacterium que los producen.
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP2308566B1 (en) 2005-04-08 2017-07-05 The Procter and Gamble Company Use of orally administered probiotic bifidobacteria for human beauty benefits
AU2011205121B2 (en) * 2005-04-08 2012-07-05 Alimentary Health Ltd Method of use of orally administered probiotic bifidobacteria for human beauty benefits
DE602006006997D1 (de) * 2005-05-16 2009-07-09 Univ Liege Probiotische bifidobacterium arten
AR053805A1 (es) 2005-05-31 2007-05-23 Iams Company Bifidobacterias probioticas para felinos
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
WO2007058027A1 (ja) 2005-11-18 2007-05-24 Idemitsu Kosan Co., Ltd. バチルス・チューリンゲンシスを含む有害菌の防除剤
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
DK2002842T3 (da) * 2006-03-31 2012-05-07 Morinaga Milk Industry Co Ltd Fremgangsmåde til fremstilling af interleukinproduktionsregulator
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080118473A1 (en) * 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
ATE521358T1 (de) * 2007-01-17 2011-09-15 Meiji Co Ltd Vorbeugender und/oder therapeutischer wirkstoff zur behandlung einer funktionellen gastrointestinalen erkrankung
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
MY151892A (en) * 2007-02-28 2014-07-14 Mjn Us Holdings Llc Product containing inactivated probiotic for infants
JP5538209B2 (ja) 2007-03-28 2014-07-02 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
JP2010522553A (ja) * 2007-03-28 2010-07-08 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
ES2578261T3 (es) 2007-05-18 2016-07-22 Nestec S.A. Lactobacillus johnsonii para prevenir infecciones postoperatorias
EP2179028B1 (en) 2007-06-27 2014-08-13 Laboratorios Ordesa, S.l. A novel strain of bifidobacterium and active peptides against rotavirus infections
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
ES2729765T3 (es) * 2009-06-19 2019-11-06 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
TR201807143T4 (tr) * 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
US20110091431A1 (en) * 2009-10-09 2011-04-21 Prothera, Inc. Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
CN107574131A (zh) * 2009-11-11 2018-01-12 营养健康有限公司 益生菌双歧杆菌菌株
WO2011148219A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
WO2011148220A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance
EP2600877A4 (en) 2010-08-04 2014-05-07 Borody Thomas J COMPOSITIONS FOR FLORAL TRANSPLANTATION OF FECAL MATERIALS AND METHODS OF MAKING AND USING SAME, AND DEVICES FOR THEIR ADMINISTRATION
WO2012031186A1 (en) 2010-09-03 2012-03-08 Wisconsin Pharmacal Company, Llc. Prebiotic suppositories
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
PL2651423T3 (pl) 2010-12-17 2016-05-31 Gervais Danone Sa Szczepy lactococcus lactis do stosowania w poprawie stanu trawienia
EP2683390B1 (en) 2011-03-09 2017-05-03 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
CN102899261B (zh) * 2011-03-11 2016-12-07 光晟生物科技股份有限公司 长双歧杆菌长亚种br022菌株的用途
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104364394B (zh) * 2012-03-17 2019-02-22 加州大学评议会 痤疮的快速诊断和个体化治疗
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
WO2015112292A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Web comprising a microorganism-containing fibrous element and method for making same
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
CA2935942A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Filaments comprising a microorganism and method for making same
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
PT3193901T (pt) 2014-12-23 2018-06-29 4D Pharma Res Ltd Polipéptido de pirina e modulação imunitária
EP3065748B1 (en) 2014-12-23 2017-11-22 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
MX2017014488A (es) 2015-05-14 2018-06-11 Crestovo Holdings Llc Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos.
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE046770T2 (hu) 2015-06-15 2020-03-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2753779T3 (es) 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
ES2662617T3 (es) 2015-11-20 2018-04-09 4D Pharma Research Limited Composiciones que comprenden cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2017226831B2 (en) 2016-03-04 2018-10-04 4D Pharma Plc Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3448398A4 (en) 2016-04-21 2019-12-18 Naked Biome, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2018158309A1 (en) 2017-02-28 2018-09-07 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
WO2018158306A1 (en) * 2017-02-28 2018-09-07 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
TW201907929A (zh) 2017-05-22 2019-03-01 英商4D製藥研究有限公司 包含細菌品系之組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
CA3064773A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
TW201919668A (zh) 2017-06-14 2019-06-01 英商4D製藥研究有限公司 包含細菌品系之組成物
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
US20190298783A1 (en) * 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress
CN108570434A (zh) * 2018-05-10 2018-09-25 苏州博悦曼环保科技有限公司 高效降解餐厨垃圾的复合菌剂及其制造方法
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
CN109929773B (zh) * 2019-01-10 2020-06-19 江苏德禧生物科技有限公司 一株可用于富硒培养的双歧杆菌及其活性蛋白和应用
CN111334486B (zh) * 2019-04-30 2021-10-08 中国科学院天津工业生物技术研究所 活性提高的磷酸转酮酶及在生产代谢物中的应用
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN116083327B (zh) * 2023-04-07 2023-06-09 天赋能(天津)功能食品研究发展有限公司 长双歧杆菌婴儿亚种及在缓解便秘、抗结肠组织炎症和改善肠道菌群方面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius

Also Published As

Publication number Publication date
IL160048A0 (en) 2004-06-20
IN2004KO00093A (es) 2006-03-03
US20060121015A1 (en) 2006-06-08
EP1409644A1 (en) 2004-04-21
US20030092163A1 (en) 2003-05-15
JP2005508617A (ja) 2005-04-07
CA2454803A1 (en) 2003-02-06
CN1561387A (zh) 2005-01-05
AU2002329006A1 (en) 2003-02-17
MXPA04000738A (es) 2004-07-08
BR0211442A (pt) 2004-11-09
WO2003010297A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
PE20030284A1 (es) Cepas de bifidobacterium
PE20030283A1 (es) Cepas de lactobacillus casei
Zeng et al. Cutting edge: probiotics and fecal microbiota transplantation in immunomodulation
Fuller Probiotics 2: applications and practical aspects
Abatenh et al. Health benefits of probiotics
CN103547276A (zh) 保护免受上呼吸道感染的非复制性益生菌微生物
US11273187B2 (en) Method and system for reducing the likelihood of developing depression in an individual
IL144184A0 (en) Use of lactobacillus salivarius
SK17172001A3 (sk) Kompozícia baktérií mliečneho kvasenia a jej použitie na prevenciu a/alebo liečenie infekcií a zápalových stavov
Finamore et al. Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats
ES2285460T3 (es) Composicion probiotica que comprende al menos dos cepas bacterianas de acido lactico capaces colonizar tractos gastrointestinales junto con posesion de propiedades de supervivencia intestinal, de union intestinal, de proteccion frente a infecciones y de fermentacion de fibras.
WO2000071138A3 (en) Oral administration of lactobacillus for the maintenance of health in women
PT1485463E (pt) Estirpes de lactobacillus
Anilkumar et al. Role of friendly bacteria in oral health-a short review.
US20210085729A1 (en) Food, cosmetic and pharmaceutical formulation with an immunomodulatory and protective anti-viral effect
CN103282040A (zh) 保护儿童免于肠胃感染的非复制性益生菌微生物
US20200179458A1 (en) Microorganisms for use and delivery to the respiratory system
ES2321602T3 (es) Composicion para fomentar la proliferacion de lactobacillus casei subsp.casei.
Agrawal et al. Role of'live microorganisms'(probiotics) in prevention of caries: Going on the natural way towards oral health
Tahmourespour Probiotics and the reduction of dental caries risk
MX2009006887A (es) Agentes para promover la produccion de iga.
CN111557499A (zh) 防护型口罩
TWM602906U (zh) 黃金克菲爾菌之外層微粒包埋結構
Grewal et al. Probiotics in health and disease
Dahiwade et al. Probiotics and Prebiotics: Current Role in Oral Health.

Legal Events

Date Code Title Description
FD Application declared void or lapsed